Associated Papers
Factor IX antibodies and tolerance in hemophilia B in the Nordic countries - The impact of F9 variants and complications.
Kihlberg K et al.
Thrombosis Research, 2022
The Molecular Basis of FIX Deficiency in Hemophilia B.
Shen G et al.
International Journal of Molecular Sciences, 2022
Molecular analysis of 76 Chinese hemophilia B pedigrees and the identification of 10 novel mutations.
Huang L et al.
Molecular Genetics & Genomic Medicine, 2020
Identification of candidate nonsense mutations of FVIII for ribosomal readthrough therapy.
Liu Z et al.
Haematologica, 2019
Specific factor IX mRNA and protein features favor drug-induced readthrough over recurrent nonsense mutations.
Branchini A et al.
Blood, 2017
Hemophilia B: molecular pathogenesis and mutation analysis.
Goodeve AC
Journal of Thrombosis and Haemostasis : Jth, 2015
25851415 (PubMed )
Supplement: JTH-13-1184-s001.docx
Risk factors associated with inhibitor development in Chinese patients with haemophilia B.
Zhou J et al.
Haemophilia : the Official Journal of the World Federation of Hemophilia, 2015
Assessment of the F9 genotype-specific FIX inhibitor risks and characterisation of 10 novel severe F9 defects in the first molecular series of Argentinian patients with haemophilia B.
Radic CP et al.
Thrombosis and Haemostasis, 2013
Allelic heterogeneity of molecular events in human coagulation factor IX in Asian Indians. Mutation in brief #965. Online.
Mahajan A et al.
Human Mutation, 2007
The spectrum of SLC17A5-gene mutations resulting in free sialic acid-storage diseases indicates some genotype-phenotype correlation.
Aula N et al.
American Journal of Human Genetics, 2000
Select a paper to view details